| RESEARCH PAPER |
|
| Year : 2005 | Volume
: 37
| Issue : 5 | Page : 320-324 |
"Quick Cycle" neoadjuvant chemotherapy in squamous cell carcinoma of cervix
A Taneja1, Shalini Rajaram2, S Agarwal3, KC Singh2, S Sahni4, N Goel2
1 Department of Obstetrics & Gynecology, Dayanand Medical College &Hospital, Ludhiana, Punjab, India
2 Department of Obstetrics and Gynecology, University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi, India
3 Department of Pathology, University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi, India
4 Specialty Ranbaxy, Mumbai, Maharashtra, India
Correspondence Address:
Shalini Rajaram
B-704 Gitanjali Apartments, Vikas Marg Extension, Delhi-110 092
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.16857
Objective: To evaluate the efficacy and safety of a 'Quick cycle' neoadjuvant chemotherapeutic regime in squamous cell carcinoma (SCC) of cervix and monitor the response to chemotherapy using Squamous Cell Carcinoma Antigen (SCC-Ag) as tumor marker.
Materials and Methods: Thirty patients with SCC of cervix (Stage I-IV) entered the study to receive three courses of multiagent neoadjuvant chemotherapy (vincristine, cisplatin and bleomycin) in a weekly regime. SCC-Ag was evaluated in these patients' pre and post-chemotherapy.
Results: Patients with stage IB2 had a complete response and two of seven patients with stage IIB became operable. The overall response rate was 47.8% and complete response rate was 8.7%. Decrease in tumor volume post-chemotherapy was significant (P<0.002). Toxicity including myelosuppression was minimal. A statistically significant decrease in SCC-Ag (stage II and III) was seen post-chemotherapy (P <0.04 and 0.005, respectively).
Conclusion: The weekly chemotherapeutic regime was found to be safe and effective and SCC-Ag is a useful tumor marker for monitoring response to chemotherapy.
[FULL TEXT] [PDF]*
|
